Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial
暂无分享,去创建一个
A. Borobia | B. Clotet | J. Prado | M. Plana | Á. Soriano | R. Ramos | M. Cañete | J. Blanco | P. Mcskimming | B. Trinité | D. Raïch-Regué | J. Arribas | M. Álvarez-Mon | J. Moltó | Natale Imaz-Ayo | E. Arana-Arri | S. Romero | J. Navarro-Pérez | A. Prenafeta | M. Cañete | A. Moros | Susana Meijide | L. Bailón | N. Izquierdo-Useros | R. Pérez-Caballero | O. Blanch-Lombarte | Antonio Barreiro | I. Esteban | Carmen Pastor-Quiñones | S. Benet | J. Parada | L. González-González | P. M. García | A. Comès | C. Sans-Pola | M. Plana | E. Pradenas | R. Ramos | L. Ferrer | D. Raich-Regue | B. Clotet | J. Corominas | C. Garriga | A. Barreiro | A. Soriano | E. Torroella | R. Lucas | M. Gallemí | M. J. Forner Giner | Laia Madrenas | Júlia Corominas | Carme Garriga | C. Pastor-Quiñones | J. Arribas | D. Troncoso | Javier Queiruga Parada | A. Barrero | L. Madrenas | I. Guell | N. Izaquierdo-Useros | X. Nunez-Costa | R. A. Taleb | J. Planol | J. O. Anagua | R. M. Lluch | X. M. Gómez | Oscar Blanch-Lombarte | Luis González-González | Carla Sans-Pola | Irina Güell | Xavier Núñez-Costa | Rachel Abu Taleb | Jocelyn Nava | Jesse Omar Anagua | Ruth Martí Lluch | Aida Corpes Comes | Susana Otero Romero | X. M. Gomez | María del Mar Vázquez Jiménez | Salvador Oña Compán | Sofía de la Villa Martínez | Sara Rodríguez Fernández | T. Prat | Laura Ferrer | J. Corominas | È. Torroella
[1] Xing Wu,et al. Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines , 2022, Frontiers in Immunology.
[2] N. Hulo,et al. Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2 , 2022, Nature Medicine.
[3] A. Almeman,et al. Management of COVID-19 vaccines cold chain logistics: a scoping review , 2022, Journal of pharmaceutical policy and practice.
[4] Chao Zhang,et al. Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies , 2022, Nature Communications.
[5] M. Koopmans,et al. Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients , 2022, Science Immunology.
[6] L. Poon,et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination , 2022, Nature Medicine.
[7] V. Libri,et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial , 2021, The Lancet.
[8] Rui Wang,et al. Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance , 2021, ArXiv.
[9] E. Dolgin. How protein-based COVID vaccines could change the pandemic , 2021, Nature.
[10] D. Vaughn,et al. Scientific rationale for developing potent RBD-based vaccines targeting COVID-19 , 2021, npj Vaccines.
[11] K. Stiasny,et al. Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action , 2021, NPJ vaccines.
[12] A. Folgori,et al. Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19 , 2021, npj Vaccines.
[13] M. V. Van Kerkhove,et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[14] M. Davenport,et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.
[15] D. Altmann,et al. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2 , 2021, npj Vaccines.
[16] Hannah Ritchie,et al. A global database of COVID-19 vaccinations , 2021, Nature Human Behaviour.
[17] Y. Zhang,et al. Blockade of SARS-CoV-2 spike protein-mediated cell–cell fusion using COVID-19 convalescent plasma , 2021, Scientific Reports.
[18] L. Du,et al. SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies , 2021, Signal Transduction and Targeted Therapy.
[19] Esteban Ortiz Prado,et al. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates , 2021, NPJ vaccines.
[20] R. Paredes,et al. Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes , 2021, Med.
[21] Nguyen H. Tran,et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. , 2020, Lancet.
[22] M. Landini,et al. Body Localization of ACE-2: On the Trail of the Keyhole of SARS-CoV-2 , 2020, Frontiers in Medicine.
[23] Y. Hu,et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial , 2020, The Lancet.
[24] Barney S. Graham,et al. Rapid COVID-19 vaccine development , 2020, Science.